Press Release:
3 New Centers Begin Certification Training
to Implant SynCardia’s Total Artificial Heart
Tripleheader Training Features 2 Hospitals from Turkey and 1 from France
TUCSON, Ariz. – Feb. 3, 2010 – On Feb. 1 and 2, surgical teams from Turkiye Yuksek Ihtisas Hospital in Ankara, Turkey, Yeditepe University Hospital in Istanbul and University Hospital of Bordeaux in France, completed the first phase of certification training in Paris to implant the SynCardia temporary CardioWest™ Total Artificial Heart.

Assoc. Prof. Drs. Mehmet Ali Ozatik (right) and Seref Alp Kucuker, Turkiye Yuksek Ihtisas Hospital
“The CE approval of the new Companion Driver System in Europe has provided us with the supply of implant drivers we need to meet demand from centers around the world who want to become certified to implant the Total Artificial Heart,” said Mary Pat Sloan, Vice President of Global Training and Customer Support. “Once stable, Total Artificial Heart patients can be switched to the European portable driver and discharged from the hospital to wait for a matching donor heart at home.”
Turkiye Yuksek Ihtisas Hospital and Yeditepe University Hospital are the 2nd and 3rd hospitals in Turkey and the 47th and 48th in the world to begin training on the SynCardia Total Artificial Heart. University Hospital of Bordeaux is the 5th hospital in France and the 49th in the world to begin certification training.
- Turkiye Yuksek Ihtisas Hospital
- Performs approximately 1,900 open heart surgeries each year, the
2nd highest amount performed by a hospital in Turkey. It is the only
Prof. Dr. Deniz Süha Küçükaksu (middle) with Erman Pektok, MD (left) and Halit Yerebakan, MD, Yeditepe University Hospital
state hospital with active cardiac transplantation and mechanical
assist device programs.
Attended training:
o Assoc. Prof. Dr. Mehmet Ali Ozatik – Chief Surgeon/
Anticoagulation
o Assoc. Prof. Dr. Seref Alp Kucuker – Surgeon/Anticoagulation/
Drivers
- Yeditepe University Hospital
- Only hospital in Istanbul with a long-term mechanical assist device program. The hospital’s state-of-the-art software allows patient vital signs such as EKG, blood pressure, respiration and temperature to be transferred from the hospital bed headboards to the personal
computers of cardiovascular surgeons.
Attended training:
L to R: Drs. Emmanuel Munos, Alain Remy, Laurent Barandon and Karine Nubret, University Hospital of Bordeaux, with proctor Prof. Pascal Leprince, La Pitié Hospital
o Prof. Dr. Deniz Süha Küçükaksu – Chief Surgeon
o Erman Pektok, MD – Surgeon/Anticoagulation
o Halit Yerebakan, MD – Trainee in Cardiovascular
Surgery/Drivers - University Hospital of Bordeaux
- Has performed more than 1,700 cardiac surgeries over the last three years.
Attended training:
o Dr. Emmanuel Munos – Cardiac Surgeon
o Dr. Laurent Barandon – Cardiac Surgeon
o Dr. Karine Nubret – Anesthesiologist
o Dr. Alain Remy – Anesthesiologist
###
About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, SynCardia's Total Artificial Heart is currently approved as a bridge to transplant for people dying from end-stage biventricular heart failure. There have been more than 950 implants of the Total Artificial Heart, accounting for more than 230 patient years of life.
Similar to a heart transplant, SynCardia's Total Artificial Heart replaces both failing heart ventricles and the four heart valves, eliminating the symptoms and source of end-stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers and does not require expensive anti-rejection medication, which can cause subsequent complications. It is the only device that provides immediate, safe blood flow of up to 9.5 liters per minute through both ventricles. This high volume of safe blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.
SynCardia Ranked #20 Among World's 50 Most Innovative Companies
In March 2011, Fast Company magazine ranked SynCardia #20 in its annual list of the "World's 50 Most Innovative Companies" for "giving mobility to artificial heart recipients." Weighing 13.5 pounds, SynCardia's Freedom® portable driver is the world's first wearable driver designed to power the Total Artificial Heart both inside and outside the hospital. The Freedom driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S.
For additional information, please visit: http://www.syncardia.com
Like SynCardia on Facebook
Follow SynCardia on Twitter – @SynCardia
Connect with SynCardia on LinkedIn
Media Contact:
Don Isaacs
Vice President of Communications
SynCardia Systems, Inc.
Cell: (520) 955-0660
SynCardia temporary CardioWest™ Total Artificial Heart.

